"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approved tisagenlecleucel (Kymriah) for treatment of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy

FDA Approved tisagenlecleucel (Kymriah) for treatment of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy

29 Jun 2018 9:30 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis), a CD19-directed genetically modified autologous T-cell immunotherapy, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software